Moderna Sets July 31 Q2 Earnings Call, Wins EU RSV Vaccine Contract
MRNA•Moderna will host its Q2 2026 earnings call and webcast on July 31, with live and archived streams available via its investor website. The company also secured a European Commission contract to supply its RSV vaccine to six EU countries, expanding its mRNA vaccine portfolio and potential revenue streams.
1. Q2 2026 Earnings Call Details
Moderna will report second quarter 2026 financial results on Friday, July 31, hosting a live conference call and webcast at 8:00 a.m. ET. The live webcast will be available under the Events and Presentations section of the company website, with an archived recording posted two hours later and retained for one year.
2. European RSV Vaccine Supply Contract
The company secured a European Commission agreement to deliver its respiratory syncytial virus vaccine to six member states. This contract marks Moderna’s first bloc-wide RSV deal and bolsters its mRNA vaccine offerings, positioning the company for increased product revenues in the respiratory disease segment.
